Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors.

Pei Pei Chong, Joshua B Rubin, Maha Abdullah, Fabio Conforti, Sabra L Klein, Wanli Liu

Abstract readEditorial

In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Temporal muscle thickness is associated with immunotherapy outcomes in head and neck squamous cell carcinoma.PloS one · 2026
Article
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.Acta oncologica (Stockholm, Sweden) · 2024
Article
Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.Annals of medicine and surgery (2012) · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pei Pei ChongSchool of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.

Joshua B RubinSchool of Medicine, Washington University at St. Louis, St. Louis, MO, United States.

Maha AbdullahDepartment of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.

Fabio ConfortiDivision of Medical Oncology for Melanoma, Sarcoma & Rare Tumours, European Institute of Oncology (IEO), Milan, Italy.

Sabra L KleinW Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD, United States.

Wanli LiuSchool of Life Sciences, Institute for Immunology, Ministry of Education (MOE) Key Laboratory of Protein Sciences, Beijing Advanced Innovation Center for Structural Biology, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsFemaleHumansImmunotherapyMaleSex FactorsAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitorsage and sexage and sex-based different immune responsesanti-CTLA-4cancer immunotherapyimmune checkpoint inhibitorsPD-1/PD-L1

Identifiers

PMID35784358

DOI10.3389/fimmu.2022.941254

PMCPMC9244535

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.